Literature DB >> 22750215

Inhibition of Eph receptor-ephrin ligand interaction by tea polyphenols.

Roberta Noberini1, Mitchell Koolpe, Ilaria Lamberto, Elena B Pasquale.   

Abstract

Tea contains a variety of bioactive chemicals, such as catechins and other polyphenols. These compounds are thought to be responsible for the health benefits of tea consumption by affecting the function of many cellular targets, not all of which have been identified. In a high-throughput screen for small molecule antagonists of the EphA4 receptor tyrosine kinase, we identified five tea polyphenols that substantially inhibit EphA4 binding to a synthetic peptide ligand. Further characterization of theaflavin monogallates from black tea and epigallocatechin-3,5-digallate from green tea revealed that these compounds at low micromolar concentrations also inhibit binding of the natural ephrin ligands to EphA4 and several other Eph receptors in in vitro assays. The compounds behave as competitive EphA4 antagonists, and their inhibitory activity is affected by amino acid mutations within the ephrin binding pocket of EphA4. In contrast, the major green tea catechin, epigallocatechin-3-gallate (EGCG), does not appear to be an effective Eph receptor antagonist. In cell culture assays, theaflavin monogallates and epigallocatechin-3,5-digallate inhibit ephrin-induced tyrosine phosphorylation (activation) of Eph receptors and endothelial capillary-like tube formation. However, the wider spectrum of Eph receptors affected by the tea derivatives in cells suggests additional mechanisms of inhibition besides interfering with ephrin binding. These results show that tea polyphenols derived from both black and green tea can suppress the biological activities of Eph receptors. Thus, the Eph receptor tyrosine kinase family represents an important class of targets for tea-derived phytochemicals.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22750215      PMCID: PMC3677025          DOI: 10.1016/j.phrs.2012.05.010

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  56 in total

Review 1.  Targeting Eph receptors with peptides and small molecules: progress and challenges.

Authors:  Roberta Noberini; Ilaria Lamberto; Elena B Pasquale
Journal:  Semin Cell Dev Biol       Date:  2011-10-25       Impact factor: 7.727

Review 2.  Regulation of angiogenesis by Eph-ephrin interactions.

Authors:  Sanne Kuijper; Christopher J Turner; Ralf H Adams
Journal:  Trends Cardiovasc Med       Date:  2007-07       Impact factor: 6.677

3.  Identification and cloning of ELF-1, a developmentally expressed ligand for the Mek4 and Sek receptor tyrosine kinases.

Authors:  H J Cheng; J G Flanagan
Journal:  Cell       Date:  1994-10-07       Impact factor: 41.582

Review 4.  Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications.

Authors:  Brahma N Singh; Sharmila Shankar; Rakesh K Srivastava
Journal:  Biochem Pharmacol       Date:  2011-07-30       Impact factor: 5.858

5.  Direct inhibition of insulin-like growth factor-I receptor kinase activity by (-)-epigallocatechin-3-gallate regulates cell transformation.

Authors:  Ming Li; Zhiwei He; Svetlana Ermakova; Duo Zheng; Faqing Tang; Yong-Yeon Cho; Feng Zhu; Wei-Ya Ma; Yuk Sham; Evgeny A Rogozin; Ann M Bode; Ya Cao; Zigang Dong
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-03       Impact factor: 4.254

6.  EphB ligand, ephrinB2, suppresses the VEGF- and angiopoietin 1-induced Ras/mitogen-activated protein kinase pathway in venous endothelial cells.

Authors:  Injune Kim; Young Shin Ryu; Hee Jin Kwak; So Young Ahn; Jong-Lark Oh; George D Yancopoulos; Nicholas W Gale; Gou Young Koh
Journal:  FASEB J       Date:  2002-05-21       Impact factor: 5.191

7.  Regeneration-enhancing effects of EphA4 blocking peptide following corticospinal tract injury in adult rat spinal cord.

Authors:  Jez Fabes; Patrick Anderson; Caroline Brennan; Stephen Bolsover
Journal:  Eur J Neurosci       Date:  2007-10-26       Impact factor: 3.386

8.  Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth.

Authors:  Nicole K Noren; Mark Lu; Andrew L Freeman; Mitchell Koolpe; Elena B Pasquale
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-05       Impact factor: 11.205

9.  Inhibition of tumor growth and angiogenesis by soluble EphB4.

Authors:  Georg Martiny-Baron; Thomas Korff; Florence Schaffner; Norbert Esser; Stefan Eggstein; Dieter Marmé; Hellmut G Augustin
Journal:  Neoplasia       Date:  2004 May-Jun       Impact factor: 5.715

10.  PEGylation potentiates the effectiveness of an antagonistic peptide that targets the EphB4 receptor with nanomolar affinity.

Authors:  Roberta Noberini; Sayantan Mitra; Ombretta Salvucci; Fatima Valencia; Srinivas Duggineni; Natalie Prigozhina; Ke Wei; Giovanna Tosato; Ziwei Huang; Elena B Pasquale
Journal:  PLoS One       Date:  2011-12-14       Impact factor: 3.240

View more
  9 in total

1.  Design, synthesis and characterization of novel small molecular inhibitors of ephrin-B2 binding to EphB4.

Authors:  Srinivas Duggineni; Sayantan Mitra; Roberta Noberini; Xiaofeng Han; Nan Lin; Yan Xu; Wang Tian; Jing An; Elena B Pasquale; Ziwei Huang
Journal:  Biochem Pharmacol       Date:  2012-12-17       Impact factor: 5.858

2.  Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor.

Authors:  Matteo Incerti; Massimiliano Tognolini; Simonetta Russo; Daniele Pala; Carmine Giorgio; Iftiin Hassan-Mohamed; Roberta Noberini; Elena B Pasquale; Paola Vicini; Silvia Piersanti; Silvia Rivara; Elisabetta Barocelli; Marco Mor; Alessio Lodola
Journal:  J Med Chem       Date:  2013-03-22       Impact factor: 7.446

3.  UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations.

Authors:  I Hassan-Mohamed; C Giorgio; M Incerti; S Russo; D Pala; E B Pasquale; I Zanotti; P Vicini; E Barocelli; S Rivara; M Mor; A Lodola; M Tognolini
Journal:  Br J Pharmacol       Date:  2014-08-28       Impact factor: 8.739

Review 4.  Tie2 and Eph receptor tyrosine kinase activation and signaling.

Authors:  William A Barton; Annamarie C Dalton; Tom C M Seegar; Juha P Himanen; Dimitar B Nikolov
Journal:  Cold Spring Harb Perspect Biol       Date:  2014-03-01       Impact factor: 10.005

Review 5.  Therapeutic potential of targeting the Eph/ephrin signaling complex.

Authors:  Nayanendu Saha; Dorothea Robev; Emilia O Mason; Juha P Himanen; Dimitar B Nikolov
Journal:  Int J Biochem Cell Biol       Date:  2018-10-19       Impact factor: 5.085

Review 6.  Role of Phytochemicals in Cancer Prevention.

Authors:  Alok Ranjan; Sharavan Ramachandran; Nehal Gupta; Itishree Kaushik; Stephen Wright; Suyash Srivastava; Hiranmoy Das; Sangeeta Srivastava; Sahdeo Prasad; Sanjay K Srivastava
Journal:  Int J Mol Sci       Date:  2019-10-09       Impact factor: 5.923

7.  Halogenated Flavonoid Derivatives Display Antiangiogenic Activity.

Authors:  Mai Khater; Kimberly A Watson; Samuel Y Boateng; Francesca Greco; Helen M I Osborn
Journal:  Molecules       Date:  2022-07-25       Impact factor: 4.927

8.  Identification of Eph receptor signaling as a regulator of autophagy and a therapeutic target in colorectal carcinoma.

Authors:  Michael DiPrima; Dunrui Wang; Alix Tröster; Dragan Maric; Nekane Terrades-Garcia; Taekyu Ha; Hyeongil Kwak; David Sanchez-Martin; Denis Kudlinzki; Harald Schwalbe; Giovanna Tosato
Journal:  Mol Oncol       Date:  2019-10-23       Impact factor: 6.603

Review 9.  The roles of Eph receptors, neuropilin-1, P2X7, and CD147 in COVID-19-associated neurodegenerative diseases: inflammasome and JaK inhibitors as potential promising therapies.

Authors:  Hamidreza Zalpoor; Abdullatif Akbari; Azam Samei; Razieh Forghaniesfidvajani; Monireh Kamali; Azadeh Afzalnia; Shirin Manshouri; Fatemeh Heidari; Majid Pornour; Majid Khoshmirsafa; Hossein Aazami; Farhad Seif
Journal:  Cell Mol Biol Lett       Date:  2022-02-02       Impact factor: 5.787

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.